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Abstract
Background:  The QUALIOST®  was designed for use with the SF-36 to measure established
osteoporosis-specific quality of life (QoL). The reliability (internal consistency and test-retest) and validity
of the questionnaire were established in a stand-alone psychometric validation study. The objective of this
paper is to provide additional information on the instrument's responsiveness using clinical trial data, along
with the reliability and validity of translated versions.
Methods: The Spinal Osteoporosis Therapeutic Intervention (SOTI) was an international clinical trial
comparing strontium ranelate to placebo on the occurrence of new vertebral fracture in patients with
postmenopausal osteoporosis. QoL was a secondary endpoint, assessed using the SF-36 and QUALIOST®
at baseline and every six months, with the main analysis at 3-year follow-up. Questionnaire acceptability,
analysis of the hypothesised structure, internal consistency reliability and responsiveness to clinical change
over time were assessed at the 3-year follow up.
Results: 1592 patients from 11 countries completed at least one QoL questionnaire. The psychometric
properties of the questionnaires were assessed on cross-sectional (N = 1486) and longitudinal (N = 1288)
data. Item discriminant validity of the QUALIOST® was excellent, as was item convergent validity, with
100% of item-scale correlations being above the 0.40 level. Internal consistency reliability was also
extremely good, with high Cronbach's alpha scores above the 0.70 benchmark. Responsiveness results
were consistent for all QUALIOST® scores, indicating that greater decreases in QoL corresponded to
greater numbers of fractures experienced. QUALIOST® scores also differed according to the type of
fracture suffered. This was demonstrated by increased effect sizes for more severe vertebral fractures
(clinical vertebral and painful vertebral). In comparing responsiveness, the QUALIOST® scores were
generally more consistent than those of the SF-36. Most notably, the QUALIOST® was more responsive
with regard to painful vertebral fractures than the SF-36.
Conclusion:  The QUALIOST® is a reliable and valid tool for measuring QoL in postmenopausal
osteoporotic women. Being available in several validated language versions, it is ready to be used in a
variety of settings, including international clinical trials.
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Background
Osteoporosis is a debilitating chronic disease that can
reduce quality of life (QoL) in a variety of ways, including
diminished physical and emotional functioning. Experi-
encing fractures can lead to reduced mobility and may be
very painful, which can limit everyday activities. Reduced
activities can lead to increasing isolation, which nega-
tively impacts upon self-esteem and self-image, and
causes depression. Experiencing a vertebral fracture can
result in fear of future vertebral fractures and anxiety is
reported early in osteoporosis [1], which often also leads
to reduced activities.
In 1995, a clinical development program for a new chem-
ical entity, strontium ranelate, was implemented in post-
menopausal women with osteoporosis. The SOTI (Spinal
Osteoporosis Therapeutic Intervention) study was an
international clinical trial comparing strontium ranelate
to placebo, according to the double blind procedure, on
the occurrence of new vertebral fractures in postmenopau-
sal patients with established osteoporosis. All patients
were included after giving informed consent and the pro-
tocol was approved by the Ethics Committee. Baseline
and annual X-rays were provided and assessed by a cen-
tralised procedure (Pr C. Roux, Cochin Hospital, France).
The prevalent and incident vertebral fractures were diag-
nosed using the semi-quantitative method (HK Genant
[2]), a visual radiographic approach with specified frac-
ture definitions, routinely used in clinical studies.
QoL was a secondary endpoint, assessed at baseline and
every six months, with the main analysis at the three-year
follow-up. 1592 patients from 11 countries completed at
least one QoL questionnaire. As part of this study, a spe-
cific quality of life measure was designed. At this time,
there was a need for a short, reliable, valid and responsive
instrument to measure the impact of the disease on
patients' QoL, which would be available in several differ-
ent languages for use in international clinical trials. The
QoL instruments available at the time did not meet all of
these criteria. The Osteoporosis Quality of Life question-
naire (OQLQ) [3] in its first version had 168 questions
and the Osteoporosis Functional Disability questionnaire
(OFDQ) [4] focused mainly on pain and handicap rather
than QoL and was not generated using patient interviews.
Based on the lack of availability of a suitable instrument,
it was decided to develop the QUALIOST®, a QoL ques-
tionnaire specific to osteoporosis. Questionnaire accepta-
bility, analysis of the hypothesised structure, internal
consistency reliability and responsiveness to clinical
change over time were assessed on baseline cross-sec-
tional (N = 1486) and longitudinal data (N = 1288).
The QUALIOST® was developed as an additional module
to supplement the SF-36 generic questionnaire. The mod-
ular approach was chosen to focus on domains that were
not already covered by the generic instrument and there-
fore minimise patient burden. It focuses mainly on the
impact of vertebral fractures on QoL. The SF-36 was iden-
tified as the most appropriate generic instrument for this
purpose because it is short, validated, and already availa-
ble in many languages and has content which is relevant
to the condition.
The first stage in the development of the QUALIOST® con-
sisted of identifying relevant concepts by conducting
interviews and focus group meetings with patients in
France and the UK. A back-translation of the English ver-
sion was conducted following standard procedures [5] to
ensure consistency in the final versions.
The next step in the development was an independent val-
idation study to establish the psychometric properties of
the QUALIOST®. Internal consistency and test-retest relia-
bility, as well as analysis of the hypothesised structure,
concurrent and clinical validity of the questionnaire were
established in both languages in a population of women
with postmenopausal osteoporosis [6].
Following the successful psychometric validation of the
QUALIOST®, the next task was to assess the responsive-
ness (the ability of the questionnaire to detect a change in
QoL when a fracture occurs) of the instrument in a clinical
trial setting and validate additional language versions.
This was done during the SOTI study, which evaluated the
efficacy of strontium ranelate compared to placebo, on
the incidence of new vertebral fracture in an international
population (N = 1649) of postmenopausal osteoporotic
women. A significant 41% reduction in the relative risk of
experiencing a first new vertebral fracture (semi-quantita-
tive assessment according to HK Genant [2]) was observed
with strontium ranelate over the three-year study com-
pared to placebo [7]. In this paper, assessment of the val-
idation of the hypothesised structure, internal consistency
reliability, and responsiveness to clinical change are pre-
sented. The data from 7 countries, for which at least 80
patients had a baseline completed questionnaire, were
analysed to validate the different linguistic versions of the
QUALIOST® and to confirm the relevance of analysing
pooled data.
Methods
The Spinal Osteoporosis Therapeutic Intervention (SOTI)
study was a 12-country, double blind, randomised, con-
trolled trial, with two parallel groups of 2 g orally per day
of strontium ranelate versus placebo. Women were eligi-
ble for the study if they were at least 50 years old, had been
postmenopausal for at least five years, had experienced at
least one previous vertebral fracture and had a lumbar
bone mineral density less than or equal to 0.840 g/cm2Health and Quality of Life Outcomes 2005, 3:69 http://www.hqlo.com/content/3/1/69
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(Hologic). Study duration was five years with the main
statistical analysis planned after three years. 1649 patients
were included (1592 in the QoL population).
The primary endpoint was the incidence of patients with
a first new vertebral fracture over 3 years. Vertebral frac-
tures were diagnosed by the semi-quantitative method
(HK Genant [2]), a visual radiographic approach which
corresponds to the attribution of grades (ranging from 0
(no vertebral fracture), 1 (20% decrease of vertebra
height), 2 (between 20 and 40% decrease of vertebra
height) to 3 (severe vertebral fracture, more than 40%
decrease of vertebra height)). One of the secondary end-
points of the clinical trial was the change in QoL, which
was assessed at baseline (M0) and then every six months
using the SF-36 and QUALIOST®. The 12 countries of the
SOTI trial were Australia, Belgium, Denmark, France, Ger-
many, Greece, Hungary, Italy, Poland, Spain, Switzerland
and the UK. QoL was studied in all countries except
Greece, where no validated SF-36 questionnaire existed at
the time of study commencement.
The QUALIOST® is a 23 item questionnaire specific to
osteoporosis, focussing on vertebral fractures and meas-
ures QoL over the previous four weeks (for more details
see additional file 1: QUALIOST® Items). The QUALIOST®
was developed to be used in conjunction with the SF-36.
The items are numbered from 12 to 34, to follow on from
the SF-36 (numbered 1 to 11). It includes two dimen-
sions: Physical (10 items) and Emotional (13 items).
Scores for each dimension as well as a Total score can be
calculated by summing the items and then transforming
the sum into a score from 0 to 100 [6], where 100 indi-
cates the highest impairment and 0 the lowest impair-
ment of QoL. If more than half of the items in a
dimension are missing then the score is considered miss-
ing for that dimension. A Total score is only calculated if
both dimension scores are present. The QUALIOST® was
originally developed in UK English and French. It was
translated following standard forward-backwards tech-
niques [5] and is now also available in Danish, Dutch,
Flemish, Belgian French, Australian English, German,
Austrian German, Hungarian, Italian, Polish, and Span-
ish.
The SF-36 measures 8 multi-item dimensions (Physical
Functioning [PF], Role-Physical [RP], Bodily Pain [BP],
General Health perceptions [GH], Vitality [VT], Role-
Emotional [RE], Social Functioning [SF], Mental Health
[MH]) and provides two summary scores (Mental Com-
ponent Summary score = MCS; and Physical Component
Summary score = PCS). In addition, an item measures
health transition. The recall period is four weeks. Scores
were calculated as recommended by the authors [8,9]. For
all scores, high values indicate good QoL and low values
indicate poor QoL. The SF-36 has been thoroughly vali-
dated and used with many different diseases such as
hypertension, diabetes, congestive heart failure and can-
cer [8,9].
Questionnaire acceptability was assessed by considering
rates of missing data both in terms of missing question-
naires per visit and missing items per questionnaire. This
was assessed for each country and for overall pooled data
(combined for all countries) for both questionnaires.
The following analyses were considered at country level,
to assess whether the different language versions had sim-
ilar psychometric properties, so that data could be pooled
between countries. As some countries had few patients,
they were not analysed individually, but were included in
the overall pool. Some analyses varied from this proce-
dure, as outlined below.
The psychometric properties of both the QUALIOST® and
SF-36 were assessed on baseline cross-sectional (N =
1486) and longitudinal data (N = 1288).
Validation of the hypothesised structure of the QUAL-
IOST® was assessed at individual country level (in coun-
tries with at least 80 patients), and on pooled data. This
was performed using multitrait analysis [10] to measure
item discriminant validity (items should have a higher
correlation with their own dimension rather than with
other dimensions) and item convergent validity (each
item should be correlated with their own dimension at or
above 0.40). Evaluation of floor and ceiling levels were
performed to ensure that the questionnaire had the poten-
tial to capture an improvement or deterioration in each
patient (floor and ceiling levels refer to the percentage of
respondents having the respective lowest or highest possi-
ble score). For the QUALIOST®, a high floor (and respec-
tively a high ceiling) level would imply that the
questionnaire would not be capable of measuring an
improvement (respectively a deterioration) in QoL. Inter-
nal consistency reliability consists of measuring the extent
to which individual items are consistent with each other
and reflect a single underlying construct, and was assessed
by calculating Cronbach's alpha values, with a value of 0.7
or greater being considered as evidence of good reliability
[11]. Internal consistency reliability was assessed at coun-
try level for countries with at least 80 patients, and on
overall pooled data.
Responsiveness to change over time evaluates the ability
of the questionnaire to detect changes in clinical status, in
this case measuring changes in QoL linked to osteoporotic
fracture occurrence in osteoporosis. Groups of patients
were defined according to the occurrence or not of the fol-
lowing types of fracture: all types of osteoporotic fractureHealth and Quality of Life Outcomes 2005, 3:69 http://www.hqlo.com/content/3/1/69
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(vertebral and non vertebral fractures), vertebral fracture,
clinical vertebral fracture (defined as a vertebral fracture
which occurs with pain and/or with body height loss of ≥
1 centimetre), painful vertebral fracture (defined as verte-
bral fracture with pain) and according to the total number
of osteoporotic fractures for the categories of all types of
osteoporotic fracture.
For each group, the changes in scores between baseline
and the last evaluable questionnaire were described, with
paired t-tests being performed to assess whether the
change was statistically significant. In addition, a one-way
analysis of variance was used to compare the mean change
in QUALIOST® total score according to the number of frac-
tures (0; 1; 2; ≥ 3) that occurred. Effect sizes (ES) are usu-
ally calculated to interpret the sensitivity of scores to
clinical change [12]. ES were calculated by subtracting the
mean score at baseline from the mean score at endpoint
(last evaluable questionnaire) and dividing by the stand-
ard deviation of the change between baseline and end-
point. ES were interpreted as small (0.20), medium (0.50)
or large (0.80) [13]. It was expected that if a woman had
a fracture during the study, she would rate a lower QoL at
endpoint compared to baseline, expressed as a decrease in
scores for the SF-36 and as an increase in scores for the
QUALIOST®.
Responsiveness of the QUALIOST®  was assessed on
pooled data only; individual country analysis was not
possible due to the low number of patients who experi-
enced fractures at country level.
Results
This study was completed in June 2003. The data for the
main 3-year analysis were collected between November
1996 (first inclusion) and June 2001. A total of 1592
patients completed at least one QoL questionnaire
(QUALIOST® or SF-36 at least once during the study) (rep-
resenting 96.5% of the patients included in the trial). A
total of 1486 patients were included in the analysis of
Table 1: Summary of cross-sectional psychometric properties of the QUALIOST® by country
Scale Country N Item convergent validity Item discriminant validity Cronbach's α Floor (%) Ceiling (%)
Range of correlations Success rate (%)
Physical Australia 88 0.49–0.79 90.0 0.91 5.7 0.0
Belgium 179 0.63–0.79 100.0 0.93 1.1 0.0
France 148 0.65–0.81 90.0 0.93 0.7 0.0
Italy 360 0.56–0.70 90.0 0.89 0.6 0.0
Poland 257 0.53–0.73 90.0 0.90 0.4 0.0
Spain 107 0.48–0.79 80.0 0.89 0.0 0.0
The UK 151 0.68–0.87 80.0 0.95 1.3 0.0
Overall 1465 0.62–0.74 90.0 0.92 1.2 0.0
Emotional Australia 88 0.56–0.75 76.9 0.93 2.3 0.0
Belgium 179 0.47–0.78 84.6 0.92 0.0 0.0
France 148 0.58–0.82 100.0 0.93 0.0 0.0
Italy 360 0.55–0.74 92.3 0.92 0.0 0.0
Poland 257 0.57–0.76 92.3 0.92 0.0 0.8
Spain 107 0.47–0.81 61.5 0.93 0.0 0.0
The UK 151 0.61–0.81 84.6 0.95 0.7 0.0
Overall 1465 0.52–0.78 100.0 0.93 0.3 0.1
Total Australia 88 0.50–0.85 . 0.95 2.3 0.0
Belgium 179 0.45–0.79 . 0.95 0.0 0.0
France 148 0.59–0.80 . 0.96 0.0 0.0
Italy 360 0.55–0.75 . 0.94 0.0 0.0
Poland 257 0.52–0.80 . 0.95 0.0 0.0
Spain 107 0.45–0.85 . 0.95 0.0 0.0
The UK 151 0.59–0.87 . 0.97 0.7 0.0
Overall 1465 0.56–0.80 . 0.95 0.3 0.0
Item convergent validity success rate: 100% for each scale (all countries)Health and Quality of Life Outcomes 2005, 3:69 http://www.hqlo.com/content/3/1/69
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cross-sectional data and 1288 in the analysis of longitudi-
nal data on the psychometric properties of the QUAL-
IOST® and SF-36.
At baseline, patients were, on average, 70 years old and
the majority were living in their own home (95.7%). The
mean Body Mass Index was 26.2 (SD ± 4.1). Following
inclusion, a central reading centre confirmed that 90.2%
of patients had at least one prevalent osteoporotic frac-
ture, and 87.3% of patients had at least one vertebral frac-
ture, as determined by semi-quantitative methods.
A rapid and sustained vertebral anti-fracture efficacy of
strontium ranelate has been demonstrated in the intent-
to-treat population, with a relative risk reduction for ver-
tebral fracture of 49% (p < 0.001) in the first year of treat-
ment and 41% (p < 0.001) over 3 years. A significant
reduction of the relative risk of multiple vertebral fractures
by 36% (p = 0.02) has also been shown. There was a sig-
nificant increase in lumbar bone mineral density of
14.4% in the strontium ranelate group compared to the
placebo group (p < 0.001) and an increase of femoral
neck BMD of 8.3% (p < 0.001) over 3 years [14]. Evalua-
ble (less than 50% of missing data) baseline QoL ques-
tionnaires were available for 93.3% of patients and were
therefore included in the analyses of the hypothesised
structure and internal consistency reliability. Longitudinal
data were available for 80.9% of the patients for the
responsiveness analysis. Most of the patients completed
the questionnaire alone (70.9% at baseline) and in the
waiting room at the medical centre (64.6% at baseline)
rather than at home.
Quality of completion
There was a high return rate of questionnaires (93.5% at
baseline) and quality of completion was high for both
questionnaires: 89.3% of baseline QUALIOST® and 76.1%
of baseline SF-36 had no missing data; the mean number
of items missing per baseline questionnaire was 1.24%
(SD ± 7.07) for the QUALIOST® and 2.12% (SD ± 6.55)
for the SF-36, indicating particularly high acceptability of
the QUALIOST® instrument. By country, the percentage of
baseline questionnaires with no missing data ranged
between 84.1% in France and 93.6% in Spain for the
QUALIOST®, and between 68.9% in France and 83.5% in
Spain for the SF-36.
Validation of the hypothesised structure of the 
QUALIOST® (see Table 1)
Analysis of the cross-sectional psychometric properties by
country included validation of the questionnaires struc-
ture and internal consistency reliability for the 7 countries
that had at least 80 patients: Australia, Belgium, France,
Italy, Poland, Spain and the UK. Table 1 provides a sum-
mary of results for these individual countries, and overall
(11 countries pooled).
The item convergent validity showed excellent scaling
results for the pooled data with all item scale-correlations
above 0.40. Similar scaling success was found in all coun-
try versions of the QUALIOST®. The item discriminant
validity was good for both dimensions (physical and
emotional). For the pooled data all items except one had
the highest correlation with their own dimension (the
exception was Q30: "During the past 4 weeks, has oste-
oporosis been a daily problem?" which correlated with its
own Physical score at 0.70, and with the Emotional score
at 0.78). At country level, there were slight variations but
for most countries there was only one or two items not
meeting the criterion. The item most frequently correlated
with the competing score was Q30 (in all countries except
Belgium). Together, the item convergent validity and item
discriminant validity results demonstrated the satisfactory
validity of the QUALIOST® hypothesised structure for each
language version tested (7 countries) and for overall data
(11 countries) (see Table 1).
Table 2: Baseline QUALIOST® scores according to number of osteoporotic fractures (all types) experienced
Score No of fractures Frequency Mean SD ANOVA (p-value)
Physical 0 839 36.91 22.72 0.2330
1 274 39.94 22.63
2 81 37.84 21.65
> = 3 77 39.78 24.35
Psychological 0 840 40.07 23.07 0.1255
1 274 43.65 22.02
2 81 43.02 22.34
> = 3 77 41.00 22.76
Total 0 837 38.63 21.63 0.1341
1 274 42.04 20.92
2 81 40.77 21.15
> = 3 77 40.47 22.15
Baseline scores based on number of fractures occurring between baseline and endpointHealth and Quality of Life Outcomes 2005, 3:69 http://www.hqlo.com/content/3/1/69
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Internal consistency reliability of the QUALIOST® (see 
Table 1) and distribution of baseline scores
The results of the internal consistency reliability were
excellent in all countries and for pooled data, with α val-
ues ranging from 0.89 to 0.95 for the Physical dimension
(0.92 pooled data), from 0.92 to 0.95 (0.93 pooled data)
for the Emotional dimension, and 0.94 to 0.97 for the
Total score (0.95 pooled data).
The absence of major floor or ceiling effects indicated that
the questionnaire had the potential to capture an
improvement or deterioration in QoL for the analysed
population. The greatest percentage of respondents at
floor or ceiling for any of the QUALIOST® scores was 5.7%
(Australia: physical dimension).
The distribution of baseline QUALIOST® scores is pro-
vided in Table 2.
Validity and reliability of the SF-36
It is usually recommended to confirm the psychometric
properties of an instrument whenever it is used in a new
population [15]. Therefore, the psychometric properties
of the SF-36 were assessed in the current study popula-
tion. However, as the SF-36 is already validated [8,9],
details of the hypothesised structure analysis and internal
consistency reliability are not presented here. The item
convergent validity for the SF-36 showed that overall,
97% of item-scale correlations were greater than or equal
to 0.40. At country level, some items were below 0.40, for
example Q11c: "I expect my health to get worse" (6 out of
7 countries). The item discriminant validity of the SF-36
showed 100% scaling success for all dimensions on the
pooled data. At country level, some items did not meet the
criterion, notably in the general health perceptions
dimension. Internal consistency reliability of the SF-36
was good, with all Cronbach's alpha values for pooled
data being above 0.70 (range 0.74–0.89). At country level,
Poland and Italy were below 0.7 for the general health
perceptions dimension, as was the social functioning
dimension in Poland.
Responsiveness of the QUALIOST®
The analysis of responsiveness showed consistent results
for all 3 QUALIOST® scores, assessed according to the
number of vertebral and non-vertebral fractures that
occurred during the study. Responsiveness indicated a
greater decrease in QoL in patients with more fractures;
mean change in QUALIOST® scores for 0, 1, 2 and 3 or
more fractures can be seen in Table 3.
ES for the number of fractures also demonstrated a clear
trend of greater change with more fractures. The ES for the
number of fractures are presented in Table 3. For 3 or
more fractures the range across scores was 0.30–0.36,
indicating a small change. The mean change in scores
reached significance in the Physical dimension for those
experiencing 2 or > = 3 fractures (p = 0.0150 and p =
0.0098 respectively) using a paired t-test. In the Emo-
tional dimension the mean change in scores reached sig-
nificance for those experiencing > = 3 fractures (p =
0.0038). The Total QUALIOST® score indicated a signifi-
cant mean change from 0 for those suffering 2 fractures (p
= 0.0228) and those experiencing > = 3 fractures (p =
0.0023). The difference in mean change between the
groups experiencing different numbers of fractures
reached significance in the Physical (p = 0.0062), Emo-
tional (p = 0.0026) and Total (p = 0.0016) scores using an
ANOVA.
The QUALIOST® scores also increased according to the
type of vertebral fracture, as demonstrated by mean
change in scores and increased ES (summarised in Table
4). For more severe vertebral fractures in terms of symp-
toms, the responsiveness increased with the occurrence of
fractures in the following order: vertebral, clinical verte-
bral, painful vertebral. For osteoporotic fractures of any
type, the ES was lower than for vertebral fractures. If
Table 3: Mean change in QUALIOST® scores according to the number of osteoporotic fractures (all types) experienced
No of fracture 0 1 2 ≥3
Physical N 836 272 81 77
Mean (± 95% CI) -0.31 (± 1.38) 1.21 (± 2.48) 5.18 (± 4.09) 6.54 (± 4.84)
Effect Size -0.02 0.06 0.28 0.30
Emotional N 838 274 81 77
Mean (± 95% CI) -1.55 (± 1.33) -0.01 (± 2.29) 3.83 (± 3.98) 5.57 (± 3.65)
Effect Size -0.08 -0.00 0.21 0.34
Total N 832 272 81 77
Mean (± 95% CI) -0.92 (± 1.25) 0.46 (± 2.18) 4.41 (± 3.73) 5.99 (± 3.72)
Effect Size -0.05 0.02 0.26 0.36
Mean change measured between baseline and endpoint
ES = (mean at endpoint – mean at baseline)/standard deviation of changeHealth and Quality of Life Outcomes 2005, 3:69 http://www.hqlo.com/content/3/1/69
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patients had a fracture, they tended to have a positive
mean change in score, indicating a decrease in QoL and
patients without a fracture had a slight decrease in their
scores, indicating a small improvement in their QoL. ES
for painful vertebral fractures ranged from 0.46 to 0.61
across scores, indicating a medium change.
Comparison of responsiveness of the QUALIOST® and SF-
36
There were some differences in the responsiveness of the
two questionnaires. The QUALIOST®  scores indicated
deterioration in QoL for patients with a fracture and a very
slight improvement in QoL for patients without a fracture.
Generally, ES for the QUALIOST® were very consistent. For
those experiencing a fracture, they tended to increase by
type of fracture with the smallest ES being for those expe-
riencing osteoporotic fractures (ES range of 0.09 to 0.14)
and the largest ES being observed for those experiencing
painful vertebral fractures (range of 0.46 to 0.61). ES for
the QUALIOST® scores according to the 4 categories of
fracture are displayed in Table 4.
The SF-36 scores indicated deterioration in QoL for both
groups, with patients who had a fracture experiencing
greater deterioration. The PF dimension demonstrated
itself to be most responsive in the SF-36 (ES range of -0.26
to -0.41), with the GH dimension also being notably
responsive (ES range of -0.23 to -0.38). ES for the SF-36
scores according to the 4 categories of fracture are dis-
played in Table 5.
Discussion
Given the length of follow-up (3 years), the high return
rates of the QUALIOST® and low percentages of missing
data, this study demonstrated good acceptability of the
questionnaire. Rates of questionnaires with at least one
missing data element varied slightly between countries
but gave no cause for concern in any particular country.
Analyses of the hypothesised structure and internal con-
sistency reliability in the 7 countries with at least 80 par-
ticipants demonstrated that each of these language
versions had satisfactory psychometric properties. Item
convergent validity was excellent with all items of all ver-
sions reaching 100% scaling success. Item discriminant
validity showed the items to be highly consistent. Ten
items correlated higher with the competing scale,
although most of the items not meeting the criterion were
highly correlated with their own score and only slightly
higher with the competing score. The close correlations
between dimension scores for these items reflects the rel-
atively high correlations between the two dimensions
overall, which is required when computing a global score.
The Emotional score results were slightly weaker than the
other two scores, the weakest result being in Spain with 5
items not meeting the item discriminant validity criterion.
However, as only one item of the Emotional score pro-
duced a significantly different correlation, the results were
considered to be satisfactory. Cronbach's alpha values
being above the 0.70 threshold for all versions and scales
indicated excellent internal consistency reliability, and no
major floor or ceiling effects were observed for any score.
Altogether, these results led to confidence in being able to
analyse pooled data.
The analysis of responsiveness to clinical change showed
a consistent link between both the occurrence and
number of fractures with change in QUALIOST® scores. ES
showed greater responsiveness for sub-categories of
increasing severity in vertebral fracture according to the
following order: vertebral, clinical vertebral and painful
vertebral fractures. Although results were consistent, with
higher responsiveness obtained for increasing severity in
vertebral fractures, the ES were rather low, except for pain-
ful vertebral fractures. For fractures of any type, the low ES
can partly be explained by the fact that responsiveness was
assessed using the last completed questionnaire, and not
using a questionnaire completed immediately after the
occurrence of fractures, leaving time for at least partial
recovery. Clearly, if responsiveness had been assessed
using QoL data gathered just after the occurrence of frac-
tures, then larger mean changes and ES would have been
obtained.
Generally, when looking at responsiveness, the ES of the
QUALIOST®scores tended to be more consistent than
Table 4: Mean change in QUALIOST® scores according to type of fracture
Type of fracture Physical Emotional Total
Mean (± 95% CI) Effect Size Mean (± 95% CI) Effect Size Mean (± 95% CI) Effect Size
Osteoporotic (N = 429) 2.99 (± 1.96) 0.14 1.70 (± 1.77) 0.09 2.22 (± 1.70) 0.12
Vertebral (N = 315) 3.59 (± 2.34) 0.17 2.15 (± 2.09) 0.11 2.73 (± 2.01) 0.15
Clinical vertebral (N = 169) 4.90 (± 3.39) 0.22 3.91 (± 2.96) 0.20 4.34 (± 2.91) 0.22
Painful vertebral (N = 89) 5.84 (± 4.43) 0.61 5.62 (± 3.81) 0.46 5.71 (± 3.79) 0.59
Mean change measured between baseline and endpoint
ES = (mean at endpoint – mean at baseline)/standard deviation of changeHealth and Quality of Life Outcomes 2005, 3:69 http://www.hqlo.com/content/3/1/69
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those of the SF-36. Most notably, the QUALIOST® demon-
strated higher responsiveness than the SF-36 for painful
vertebral fractures. The GH dimension of the SF-36 was
highly responsive, demonstrating the importance in
measuring the global impact that fractures had upon
patients. Consistently higher ES were observed in the PF
dimension of the SF-36 in comparison to the Physical
component of the QUALIOST®, with the exception of
painful vertebral fractures. This could indicate that the SF-
36 is more responsive with regard to fractures of lower
limbs, especially since the PF dimension is largely con-
cerned with walking. Furthermore, the ES for the BP SF-36
dimension were inconsistent and lower than the equiva-
lent QUALIOST® scores, which could potentially indicate
the QUALIOST® to be more responsive to vertebral frac-
tures than the SF-36. This could be expected though since
the focus of the QUALIOST® is on vertebral fractures.
Therefore, it could be suggested that the SF-36 is more
responsive to limb fractures and the QUALIOST®to verte-
bral fractures, demonstrating the value of using the
QUALIOST®in conjunction with the SF-36.
When the decision was taken to create the QUALIOST®, no
other questionnaires had been published that were short,
osteoporosis-specific instruments with good psychomet-
ric properties and available in many languages. Currently,
there are several QoL instruments specific to osteoporosis,
including the OPTQoL (Osteoporosis Targeted Quality of
Life), the OPAQ (Osteoporosis Assessment Question-
naire), the QUALEFFO (Quality of life questionnaire of
the European Foundation for Osteoporosis) [16], the
OQLQ (Osteoporosis Quality of Life Questionnaire) and
the OFDQ (Osteoporosis Functional Disability Question-
naire) [17]. The OPTQoL is a cross-sectional instrument
that was developed to characterise the burden of oste-
oporosis in a community and therefore is not aimed at
assessing change over time. The OFDQ measure of pain
and disability, designed for use in longitudinal interven-
tion trials involving exercise rehabilitation for patients
with osteoporotic vertebral fractures, has demonstrated
some usefulness for tracking an individual's change over
time [4], although it has not been used in clinical trials of
medication and focuses on disability rather than QoL. The
OQLQ was administered in an osteoporotic population
with chronic back pain [3]. The questionnaire was found
to be at least as responsive as other instruments when
using a global rating of change. The authors acknowledge
that this may have limited validity in this population due
to the possible inaccuracy of patients estimating their
change. Responsiveness of the OQLQ was not based on
clinical trial data with the occurrence of fracture.
The QUALEFFO has been used in a large clinical interven-
tional trial (Multiple Outcomes of Raloxifene Evaluation,
or the MORE study) and has been able to discriminate
between groups of patients with and without incident ver-
tebral fractures (IVFX) [18]. The OPAQ was also used as
an outcome in the MORE study [19] and also seems to be
responsive to clinical changes; women with incident ver-
tebral fractures had a higher percentage of significant
HRQL loss compared with women without incident verte-
bral fractures in physical function, symptoms, and overall
HRQL (all p < 0.05) but not emotional status or social
interaction.
As can be seen, there are now several osteoporosis-specific
QoL questionnaires available. Notably the OPAQ and the
QUALEFFO have demonstrated responsiveness to clinical
change. The main issue that has been stated with the
QUALEFFO specific questionnaire is that it performs sim-
ilarly to the Physical summary score of the SF-36 in dis-
criminating between fracture cases and controls [6]. It
would be interesting to compare the discriminative prop-
erties of the QUALIOST® with those of these instruments
in future work.
As the QUALIOST® is designed to be used in conjunction
with the SF-36, the benefits of using a generic and specific
questionnaire can be attained whilst minimising burden
to patients and administrators [17]. Indeed, one of the
main strengths of the QUALIOST® compared with other
specific questionnaires such as the QUALEFFO is its meas-
urement strategy in being a supplemental specific module
complementing the SF-36 [6]. The advantages of choosing
the SF-36 include the relevance of the scores relating to
osteoporosis, its availability in many languages and exten-
sive use in many settings, which allows comparisons
between populations and conditions. It has also estab-
Table 5: Effect sizes for change in SF-36 scores according to type of fracture
Type of fracture PF RP BP GH VT SF RE MH PCS MCS
Osteoporotic (n = 436) -0.27 -0.14 -0.08 -0.25 -0.05 -0.25 -0.16 -0.15 -0.18 -0.18
Vertebral (n = 318) -0.26 -0.12 -0.11 -0.23 -0.07 -0.27 -0.15 -0.16 -0.17 -0.19
Clinical vertebral (n = 170) -0.33 -0.11 -0.09 -0.28 -0.14 -0.27 -0.17 -0.17 -0.23 -0.18
Painful vertebral (n = 89) -0.41 -0.17 -0.18 -0.38 -0.22 -0.30 -0.21 -0.30 -0.30 -0.24
Change in SF-36 scores measured between baseline and endpoint: effect sizes only presented for those experiencing a fracture
ES = (mean at endpoint – mean at baseline)/standard deviation of changeHealth and Quality of Life Outcomes 2005, 3:69 http://www.hqlo.com/content/3/1/69
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lished reference values which can be used to compare with
healthy populations, and can be adjusted for age effects,
which is useful in the target population of elderly oste-
oporotic patients.
Conclusion
The analysis results of the hypothesised structure and
internal consistency reliability of 7 languages versions of
the QUALIOST®, using data from the SOTI trial combined
with previously reported psychometric validation results
confirm the good psychometric properties of this instru-
ment. The QUALIOST® has demonstrated responsiveness
to clinical change (occurrence of new osteoporotic frac-
tures, vertebral fractures, clinical vertebral fractures, and
painful vertebral fractures). The QUALIOST® is a short,
reliable and valid tool to measure QoL in postmenopau-
sal osteoporotic women. Being available in several vali-
dated language versions, it is ready to be used in a variety
of settings, including international clinical trials.
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